Pfizer Inc. (PFE) Position Boosted by M Holdings Securities Inc.
M Holdings Securities Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 41.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,036 shares of the biopharmaceutical company’s stock after acquiring an additional 7,635 shares during the quarter. M Holdings Securities Inc.’s holdings in Pfizer were worth $875,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Altfest L J & Co. Inc. lifted its holdings in shares of Pfizer by 67.0% in the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after buying an additional 43,024 shares during the period. HL Financial Services LLC lifted its holdings in shares of Pfizer by 1.1% in the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after buying an additional 35,744 shares during the period. Sphera Funds Management LTD. purchased a new stake in shares of Pfizer in the 1st quarter worth $13,342,000. Searle & CO. lifted its holdings in shares of Pfizer by 92.7% in the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after buying an additional 38,500 shares during the period. Finally, Hartford Financial Management Inc. lifted its holdings in shares of Pfizer by 10.8% in the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 835 shares during the period. Institutional investors own 69.89% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded up $0.74 during trading hours on Friday, reaching $37.20. The company had a trading volume of 35,613,216 shares, compared to its average volume of 14,408,752. Pfizer Inc. has a 12 month low of $30.90 and a 12 month high of $37.22. The firm has a market cap of $221,708.50, a price-to-earnings ratio of 14.88, a P/E/G ratio of 2.62 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.44%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio is currently 79.01%.
Several equities research analysts have weighed in on PFE shares. BMO Capital Markets set a $37.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 10th. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $38.77.
In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Pfizer Inc. (PFE) Position Boosted by M Holdings Securities Inc.” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/17/pfizer-inc-pfe-position-boosted-by-m-holdings-securities-inc.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.